Surgery – Respiratory method or device
Patent
1997-01-07
1998-10-20
Lewis, Aaron J.
Surgery
Respiratory method or device
12820312, 12820014, A61M 1500
Patent
active
058231803
DESCRIPTION:
BRIEF SUMMARY
A 371 of PCT/US95/04/23 Apr. 3, 1995.
BACKGROUND OF THE INVENTION
This invention relates to the treatment of pulmonary vasoconstriction and to the treatment of asthma. This invention was made in the course of work supported by the U.S. Government, which has certain rights in the invention.
Asthma is a chronic disease characterized by intermittent, reversible, widespread constriction of the airways of the lungs in response to any of a variety of stimuli which do not affect the normal lung. Estimates of the prevalence of this disease in the U.S. population range from three to six percent.
In attempting to unravel the pathogenesis of asthma, the cellular and biochemical basis (sic) for three important features of the disease have been sought: chronic airway inflammation, reversible airflow obstruction, and bronchial hyperreactivity. Theories have pointed variously to abnormalities in autonomic nervous system control of airway function, in bronchial smooth muscle contractile properties, or in the integrity of the epithelial cell lining as features that distinguish asthmatic from normal airways . . . . Evidence suggests that the normal epithelial lining functions as more than a simple barrier: epithelial cells may produce a relaxing factor that actively maintains airway patency by causing relaxation of smooth muscle. Epithelial desquamation could contribute to bronchial hyperreactivity because a lesser amount of relaxing factor would be produced. ("Asthma", Ch. 14-II in Scientific American Medicine, Vol. 2; Scientific American, Inc.; 1988, p. 2, 4)
Drugs used to treat asthma fall generally into two categories: those which act mainly as inhibitors of inflammation, such as corticosteroids and cromolyn sodium, and those which act primarily as relaxants of the tracheobronchial smooth muscle, such as theophylline and its derivatives, beta-adrenergic agonists, and anticholinergics. Some of these bronchodilators may be administered orally, while others are generally given by intravenous or subcutaneous injection or by inhalation of the drug in an appropriate form, such as aerosolized powder (i.e., delivered in the form of a finely divided solid, suspended in a gas such as air), or aerosolized droplets (delivered in the form of a fine mist). Asthma patients typically self-administer bronchodilator drugs by means of a portable, metered-dose inhaler, employed as needed to quell or prevent intermittent asthma attacks.
Conceptually analogous to the narrowing of the airways of the lung which occurs in an asthma attack, vasoconstriction is a reversible narrowing of blood vessels attributable to contraction of the smooth muscle of the blood vessels. Such vasoconstriction can lead to abnormally high blood pressure (hypertension) in the affected portion of the circulatory system.
The mammalian circulatory system consists of two separate systems, the systemic circuit and the pulmonary circuit, which are pumped in tandem by the left and right sides of the heart, respectively. The pulmonary circulation transports the blood through the lungs, where it picks up oxygen and releases carbon dioxide by equilibrating with the concentrations of oxygen and carbon dioxide gas in the alveoli. The oxygen-rich blood then returns to the left side of the heart, from whence it is distributed to all parts of the body via the systemic circulation.
The systemic circulatory system of an adult human typically has a mean systemic arterial pressure ("SAP") of 80-100 mm Hg, whereas a typical mean pulmonary arterial pressure ("PAP") is approximately 12-15 mm Hg. Normal pulmonary capillary pressure is about 7-10 mm Hg. Considering the interstitial fluid colloid osmotic pressure (14 mm Hg) and the plasma colloid oncotic pressure (28 mm Hg), as well as the interstitial free fluid pressure (1-8 mm Hg), the normal lung has a +1 mm Hg net mean filtration pressure (Guyton, Textbook of Medical Physiology. 6th Ed.; W. B. Saunders Co., Philadelphia, Pa. (1981), p. 295). This nearly balanced pressure gradient keeps the alveoli of a healthy lung free of fluid whic
REFERENCES:
patent: 3745991 (1973-07-01), Gauthier et al.
patent: 3785377 (1974-01-01), Jorgensen
patent: 4010897 (1977-03-01), Treharne et al.
patent: 4287040 (1981-09-01), Alamaro
patent: 4297123 (1981-10-01), Wyse et al.
patent: 4336798 (1982-06-01), Beran
patent: 4484577 (1984-11-01), Sackner et al.
patent: 4534343 (1985-08-01), Nowacki et al.
patent: 4592348 (1986-06-01), Waters, IV et al.
patent: 4667668 (1987-05-01), Wetterlin
patent: 4852561 (1989-08-01), Sperry
patent: 4877589 (1989-10-01), O'Hare
patent: 4915915 (1990-04-01), Treharne
patent: 4954526 (1990-09-01), Keefer
patent: 5007419 (1991-04-01), Weinstein et al.
patent: 5155137 (1992-10-01), Keefer et al.
patent: 5178138 (1993-01-01), Walstrom et al.
patent: 5187305 (1993-02-01), Thompson et al.
patent: 5208233 (1993-05-01), Keefer et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5260210 (1993-11-01), Rubin et al.
patent: 5385937 (1995-01-01), Stamler et al.
patent: 5396882 (1995-03-01), Zapol
patent: 5570683 (1996-11-01), Zapol
Braner et al., M&B 22948, a cGMPP Phosphodiesterase Inhibitor, is a Pulmonary Vasodilator in Lambs, Am. J. Physiol. 264 (Heart Circ. Physiol. 33): H252-H258, 1993.
Bult et al., Nitric Oxide as an Inhibitory Non-adrenergic Non-cholinergic Neurotransmitter, Nature Lond. 345:346-347, 1990.
Inchinose et al., Prolonged Pulmonary Vasodilator Action of Inhaled Nitric Oxide by Zaprinast in Awake Lamb, J. Appln. Physiol. 78:1288-1295, 1995.
Ichinose et al., Prolonged Duration of Action of Inhaled Nitric Oxide by Zaprinast, a cGMP Phosphodiesterase Inhibitor, in Awake lambs, Am. J. Respiratory & Critical Care Medicine 149:A22, 1994.
Ichinose et al., Selective Pulmonary Vasodilation by Inhaled Nitric Oxide (NO) and Nebulized Zaprinast in Awake Lambs, Am. J. Respiratory & Critical Care Medicine 151:A730, 1995.
Winkler et al., Effects of Inhaled DEA/NO With or Without Zaprinast Pretreatment on Airway Mechanics of Guinea Pigs, Am. J. Respiratory & Critical Care Medicine 149:A592, 1994.
Shimouchi et al., cAMP Decreases Expression of Genes Encoding Soluble Guanylate Cyclase Subunits in RFL-6 Rat Lung Fibroblasts, 1992 FASEB Meeting, Anaheim, CA The FASEB Journal Abstracts Part 1, No. 5272.
Blomqvist et al., Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator Reversing Human Hypoxic Pulmonary Vasoconstriction (HPV), Abstracts From the 64th Scientific Sessions, No. 0361, II-91.
Desai et al., Involvement of Nitric Oxide in the Reflex Relaxation of the Stomach to Accommodate food or Fluid, Nature 351:477, 1991.
Donahoe et al., Production of O.sub.3, NO, and N.sub.2 O in a Pulsed Discharge at 1 Atm, Ind. Eng. Chem. 16:208-215, 1977.
Fractacci et al., Inhaled Nitric Oxide, Anesthesiology 75:990-999, 1991.
Pepke-Zaba et al., Inhaled Nitric Oxide as a Cause of Selective Pulmonary Vasodilation in Pulmonary Hypertension, The Lancet 338:1173-1174, 1991.
Rimar et al., Prolonged Duration of Inhaled Nitric Oxide Induced Vasodilation in Perfused Rabbit Lungs Abstracts from the 64th Scientific Sessions, II-91, No. 0362.
Roberts, Jr. et al., Inhaled Nitric Oxide (NO): A Selective Pulmonary Vasodilator for the Treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), Circulation 84:1279, 1991.
Dupuy et al., Bronchodilator Action of Inhaled Nitric Oxide in Guinea Pigs, J. clin. Invest. 90:421-428, 1992.
Kacmarek et al., Nitric Oxide as a Bronchodilator in Methacholine Induced Bronchospasm in Mild Asthmatics, 1993 ALA/ATS International Conference, May 16-19, 1993, San Francisco, CA #21556 (Abstract).
Messent et al., The Pulmonary Physician and Critical Care, Thorax 47:651-656, 1992.
Swami et al., The Pulmonary Physician and Critical Care, Thorax 47:555-562, 1992.
Frostell et al., Inhaled Nitric Oxide: A Selective Pulmonary Vasodilaor Reversing Hypoxic Pulmonary Vasoconstriction, Circulation 83:2038-2047, 1991.
Dalby et al., Comparison of Output Particle Size Distributions from Pressurized Aerosols Formulated as Solutions or Suspensions, Pharmac. Re. 5:36-39, 1988.
Bug
Lewis Aaron J.
The General Hospital Corporation
LandOfFree
Methods for treating pulmonary vasoconstriction and asthma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating pulmonary vasoconstriction and asthma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating pulmonary vasoconstriction and asthma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-234045